- Previous Close
13.34 - Open
13.31 - Bid 13.67 x 100
- Ask 13.76 x 100
- Day's Range
13.28 - 13.91 - 52 Week Range
11.30 - 18.07 - Volume
591,558 - Avg. Volume
1,065,545 - Market Cap (intraday)
1.384B - Beta (5Y Monthly) -1.52
- PE Ratio (TTM)
-- - EPS (TTM)
-0.97 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
37.00
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
dayonebio.comRecent News: DAWN
View MorePerformance Overview: DAWN
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DAWN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DAWN
View MoreValuation Measures
Market Cap
1.38B
Enterprise Value
827.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.00
Price/Book (mrq)
2.49
Enterprise Value/Revenue
8.12
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-82.68%
Return on Assets (ttm)
-25.43%
Return on Equity (ttm)
-17.84%
Revenue (ttm)
101.95M
Net Income Avi to Common (ttm)
-84.29M
Diluted EPS (ttm)
-0.97
Balance Sheet and Cash Flow
Total Cash (mrq)
558.38M
Total Debt/Equity (mrq)
0.47%
Levered Free Cash Flow (ttm)
-151.71M